A newly described small molecule inhibitor called AOH-1996 targets a cancer-associated isoform of PCNA (caPCNA), leading to a very broad therapeutic window. Researchers at City of Hope, a cancer research and treatment organization in California, reported on AOH-1996 in the Aug. 1, 2023, online edition of Cell Chemical Biology. Genes involved in replication and repair pathways are essential for the growth and survival of cancer cells. Proliferating cell nuclear antigen (PCNA) is a key player in DNA replication via a homotrimer formation that acts as a molecular sliding clamp around the DNA double helix.
Lantern Pharma Inc. has received IND clearance from the FDA for LP-184, which is being developed for advanced solid tumors and central nervous system (CNS) cancers.
Nodus Oncology Ltd. closed on the first £2.4 million (US$2.9 million) of £12 million it expects to raise in a number of tranches over the next 12 months, to source and take forward third-generation DNA damage response (DDR) programs.
Onxeo SA has expanded its pipeline of drug candidates with OX-425, an optimized new compound of the OX-400 series sourced from its proprietary Platon platform.
Startup Avelos Therapeutics Inc. raised $8 million in series A funding that will launch the company’s biomarker-driven cancer therapy pipeline using its synthetic lethality platform. Participating in the series A funding were SV Investment, UTC Investment, Quad Investment Management, Timepolio Asset Management, Mirae Asset Venture Investment and Mirae Asset Capital.
Nodus Oncology Ltd. is set to explore new avenues of DNA damage response by targeting the chromosome next-door neighbors of tumor suppressor genes that are damaged when tumor suppressor genes are inactivated via homozygous deletion. These collaterally deleted ‘passenger genes’ play diverse functions in cell homeostasis and so present a number of molecularly targeted vulnerabilities that can provide a route to destroying cells which carry a tumor suppressor gene.
Schrödinger Inc. has paired up with Zai Lab Ltd. to collaborate on an oncology program targeting DNA damage response (DDR) in a deal that could net Schrödinger up to $338 million.
Schrödinger Inc. has paired up with Zai Lab Ltd. to collaborate on an oncology program targeting DNA damage response (DDR) in a deal that could net Schrödinger up to $338 million.
A genome-wide association study has identified 290 genetic variants, including a wide range of DNA damage response genes, that are associated with age at menopause.
LONDON – Artios Ltd. has closed a $153 million series C, positioning it to intensify clinical development of its two lead programs, whilst applying its DNA damage response platform to exploit the full spectrum of vulnerabilities presented by inhibition of DNA damage repair enzymes.